ICRA (Improve Checkpoint-blockade Response in Advanced Urothelial Cancer), an Adaptive Clinical Study to Determine Efficacy of Combining Weekly Paclitaxel With Tremelimumab +/- Durvalumab (MEDI4736)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Durvalumab (Primary) ; Paclitaxel (Primary) ; Tremelimumab (Primary)
Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms ICRA

06 Mar 2025 Status changed from active, no longer recruiting to completed.
20 Feb 2024 Planned End Date changed from 1 May 2025 to 31 Jan 2025.
24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com